Daihan Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	211,440	208,614	204,195	195,911	184,268	171,463
Other Revenue	-0	-0	-	-	-	-0
Revenue	211,440	208,614	204,195	195,911	184,268	171,463
Revenue Growth	3.11%	2.16%	4.23%	6.32%	7.47%	3.24%
Cost of Revenue	148,355	144,169	134,788	130,599	124,455	115,781
Gross Profit	63,085	64,445	69,407	65,312	59,812	55,682
Selling, General & Admin	30,363	30,014	28,428	26,945	25,445	24,923
Research & Development	1,915	2,206	1,802	1,641	567.87	790.59
Amortization of Goodwill & Intangibles	-	-	-	-	-	0.5
Other Operating Expenses	458.84	449.95	479.63	411.75	387.26	334.4
Operating Expenses	33,271	33,259	31,327	29,517	26,844	26,614
Operating Income	29,815	31,186	38,081	35,795	32,968	29,068
Interest Expense	-2.49	-2.69	-1.81	-52.47	-593.43	-469.27
Interest & Investment Income	1,962	1,867	1,475	87.18	486.66	506.7
Currency Exchange Gain (Loss)	252.75	-239	1,229	504.71	525.35	687.03
Other Non Operating Income (Expenses)	33.98	37.28	1,184	87.57	73.92	599.56
EBT Excluding Unusual Items	32,060	32,848	41,967	36,422	33,461	30,392
Gain (Loss) on Sale of Investments	49.61	274.01	303.6	288.69	-	-
Gain (Loss) on Sale of Assets	35.02	31.38	58.03	22.53	-9.4	41.28
Pretax Income	32,145	33,153	42,329	36,734	33,451	30,433
Income Tax Expense	5,167	5,510	8,569	8,307	8,491	7,763
Net Income	26,978	27,644	33,759	28,426	24,961	22,670
Net Income to Common	26,978	27,644	33,759	28,426	24,961	22,670
Net Income Growth	-18.59%	-18.11%	18.76%	13.88%	10.10%	30.43%
Shares Outstanding (Basic)	6	6	6	6	6	6
Shares Outstanding (Diluted)	6	6	6	6	6	6
Shares Change	-	-	-	-1.75%	-0.25%	-
EPS (Basic)	4588.16	4701.33	5741.34	4834.41	4170.67	3778.40
EPS (Diluted)	4588.16	4701.33	5741.34	4834.41	4170.67	3778.40
EPS Growth	-18.59%	-18.11%	18.76%	15.92%	10.38%	30.43%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	3,124	481.53	19,841	17,580	20,378	28,767
Free Cash Flow Per Share	531.35	81.89	3374.38	2989.79	3405.01	4794.57
Gross Margin	29.84%	30.89%	33.99%	33.34%	32.46%	32.48%
Operating Margin	14.10%	14.95%	18.65%	18.27%	17.89%	16.95%
Profit Margin	12.76%	13.25%	16.53%	14.51%	13.55%	13.22%
Free Cash Flow Margin	1.48%	0.23%	9.72%	8.97%	11.06%	16.78%
EBITDA	40,312	40,406	45,362	44,459	42,176	40,479
EBITDA Margin	19.07%	19.37%	22.21%	22.69%	22.89%	23.61%
D&A For EBITDA	10,498	9,221	7,282	8,663	9,208	11,411
EBIT	29,815	31,186	38,081	35,795	32,968	29,068
EBIT Margin	14.10%	14.95%	18.65%	18.27%	17.89%	16.95%
Effective Tax Rate	16.07%	16.62%	20.24%	22.61%	25.38%	25.51%
Advertising Expenses	-	174.21	99.76	78.69	93.67	63.18